Results 171 to 180 of about 174,019 (298)

Measurement of Active Thrombin Bound to Circulating D‐Dimers as a Sensitive Biomarker for Prothrombotic Conditions

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
Scheme of preparation of D‐dimers and evaluation of D‐dimer‐bound thrombin activity. Thrombin bound to fibrin participates in ongoing fibrinogen transformation and its inhibition is impeded. Our detection system may aid in identifying patients at risk of recurrent thrombotic events or complications, regardless of the origin of the acute health problem.
Jana Stikarova   +15 more
wiley   +1 more source

Estimated impact of model‐guided venous thromboembolism prophylaxis versus real‐world practice

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Background The American Society of Hematology (ASH) recommends assessing venous thromboembolism (VTE) and major bleeding risk to optimize pharmacological VTE prophylaxis for medical inpatients. However, the clinical utility of model‐guided approaches remains unknown.
Benjamin G Mittman, Michael B. Rothberg
wiley   +1 more source

Incidence, contributing factors, and predictors of diagnostic errors in medical inpatients: A retrospective cohort study

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Background Diagnostic error is a major patient safety concern in hospitals, yet most studies have focused on selected high‐risk subgroups, leaving the broader general internal medicine inpatient population understudied. Objectives To determine the incidence, contributing factors, resulting harm, and predictors of diagnostic error in medical ...
Caterina E. Marx   +9 more
wiley   +1 more source

Things We Do for No Reason™: Prescribing gabapentinoids for pain

open access: yesJournal of Hospital Medicine, EarlyView.
Abstract Gabapentin and pregabalin are among the most frequently prescribed medications in the United States, with gabapentin in the top 10 and pregabalin in the top 100. Despite FDA approval for only select neuropathic conditions, most use is for off‐label pain indications.
Niti G. Patel   +4 more
wiley   +1 more source

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy